BCM
BNTX icon

Bayesian Capital Management’s BioNTech BNTX Stock Holding History

Bayesian Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,900
Closed -$728K – 794
2023
Q4 		$728K Buy
6,900
+700
+11% +$70.5K 0.08% 294
2023
Q3 		$674K Buy
+6,200
New +$686K 0.08% 299
2023
Q1 		– Sell
-10,400
Closed -$1.56M – 796
2022
Q4 		$1.56M Buy
10,400
+1,987
+24% +$306K 0.23% 96
2022
Q3 		$1.14M Sell
8,413
-3,087
-27% -$472K 0.23% 121
2022
Q2 		$1.72M Buy
11,500
+6,400
+125% +$978K 0.32% 69
2022
Q1 		$870K Buy
5,100
+3,637
+249% +$611K 0.13% 236
2021
Q4 		$377K Sell
1,463
-5,837
-80% -$1.6M 0.12% 220
2021
Q3 		$1.99M Buy
+7,300
New +$2.32M 0.58% 35
2021
Q1 		– Sell
-9,700
Closed -$791K – 541
2020
Q4 		$791K Buy
+9,700
New +$952K 0.21% 142

Other funds holding BNTX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Flossbach Von Storch
Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return

Bayesian Capital Management's BNTX Position: Q1 2024 in Review

Bayesian Capital Management sold out of BioNTech (BNTX) in Q1 2024, closing a stake of 6,900 shares — an estimated $728K sold.

Bayesian Capital Management first reported a position in BNTX in Q4 2020 and held it in 9 quarters. The position peaked at $1.99M in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2024.

  • Bayesian Capital Management reported no remaining BioNTech position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 6,900 BioNTech shares in Q1 2024, an estimated $728K.
  • Bayesian Capital Management first reported a position in BioNTech in Q4 2020 and held it in 9 quarters.
  • Bayesian Capital Management's BioNTech position peaked at $1.99M in Q3 2021.
  • 287 funds tracked by Wall St. Rank held BioNTech as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.